Assyro AI

Purple Book product · Reference 351(a)

StrataGraft

Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat

351(a)BLA 125730DiscVoluntarily Revoked Stratatech Corporation

At a glance

Jun 15, 2021

Approved

Reference 351(a)

License type

Disc

Marketing

No

Patents listed

Key dates

  1. First licensure

    Date the BLA was first licensed.

    Jun 15, 2021

    5 yr 1 mo ago

  2. Approval

    Approval date of this BLA submission.

    Jun 15, 2021

    5 yr 1 mo ago

  3. Today

  4. Orphan exclusivity ends

    7-year orphan-drug exclusivity window.

    Jun 15, 2028

    in 2 yr 1 mo

  5. Reference product exclusivity ends

    12-year reference-product exclusivity window per BPCIA §351(k)(7).

    Jun 15, 2033

    in 7 yr 2 mo

Pharmaceutical detail

Strength

100CM SQUARED

Dosage form

Cell Sheets

Route

Topical

Presentation

Pouch

Center

CBER

License number

2144

Product number

001

Submission type

Original

Supplement number

0

Change type

Not listed

Reference product family

View full family

This is the reference (originator) product. Biosimilars and interchangeables referencing it are listed below.

Patent list

No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.

Taxonomy and ontology

11 terms

center

Center for Biologics Evaluation and Research

center · CBER

application pathway

Biologics License Application

blaNumber · BLA

license type

351(a)

blaType · 351(a)

application pathway

Section 351(a) Biologic

blaType · 351(a)

product role

Reference or Standalone Biologic

blaType · Reference product

marketing status

Discontinued

marketingStatus · Disc

licensure status

Voluntarily Revoked

licensure · Voluntarily Revoked

source kind

Monthly Download

sourceKind · monthly_download

patent status

No Patent List Provided

patentListProvided · No patent list

exclusivity type

Reference Product Exclusivity

referenceProductExclusivityExpirationDate · Reference Product Exclusivity

  • Food and Drug Administrationparent ofCenter for Biologics Evaluation and Research
  • Food and Drug Administrationsource forMonthly Download
  • Biologics License Applicationparent ofSection 351(a) Biologic
  • Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
  • Section 351(a) Biologicmaps to351(a)
  • 351(a)classifiesReference or Standalone Biologic

Source provenance

Source kind · Monthly download
Checked May 28, 2026
FDA release · April 2026
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.